The Webinar Training Pass

Now get all the training you need – all in one place, and all for one low price!

The FDAnews Webinar Training Pass program gives you year-round unrestricted access to any of the hundreds of webinars listed below. These training programs feature top consultants, expert speakers and FDA officials.

PLUS, subscribers get automatic access to all our new training programs for the next 12 months – that’s more than 50 new programs a year!

If you are already a Training Pass member login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video click the "Download Presentation" link.

Already have an account?   Login Here.

Webinar Training Pass

Recorded on: Oct. 4, 2019

Description: Experts Julie Larsen and Lenita Sims-Spears share best practices for keeping abreast of the changes, and potential impact, brought by VMSR and NEST. They discuss:

  • The real-world impact new medical device reporting programs will have following the formal end to the ASR program;
  • How the FDA is transitioning to the VMSR program;
  • Which devices and device malfunctions are eligible, or not, for summary reporting in VSMR; and
  • The critical components of FDA’s NEST initiative and how the FDA will monitor medical device performance through NEST.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Julie Larsen, Principal Consultant and Director of Inspection Readiness Services, BioTeknica, Inc.; Lenita Sims-Spears, Senior QARA Consultant, BioTeknica, Inc.

Recorded on: Oct. 2, 2019

Description: Clinical experts Irina Petrova and Anna Yanaeva share best practices for preparing to choose the right CRO for your organization, whether they be local or globally located. They discuss:

  • How to select the right CRO — Does the CRO have global reach, local regulatory expertise, brand recognition, speed of decision-making, advanced technologies and competitive pricing;
  • What pharma-CRO relationships are like — Why are most pharma firms unsatisfied with their experiences;
  • How to choose a CRO based on therapeutic area expertise.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Irina Petrova, Director of Clinical Operations; Anna Yanaeva, Director of Business Development; OCT Clinical Trials

Recorded on: Sept. 27, 2019

Description: Regulatory experts Cynthia Schnedar and Liz Oestreich share best practices for exploring the new inspections landscape of the Mutual Recognition Agreement (MRA). They discuss:

  • The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and what it has led to;
  • How inspectors are using each other’s inspections to maintain a risk-based approach, to include potential benefits for U.S. drug safety;
  • How the MRA may complicate regulatory and compliance operations — which inspections will the FDA continue to perform, and which will be assigned to EU member states; and
  • What’s next for FDA capability assessments and the possibility of duplicating the MRA model in other regions, including the potential impact of ‘Brexit’ on the MRA.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Cynthia Schnedar Esq., Executive Vice President, Regulatory Compliance; Liz Oestreich Esq., Vice President, Regulator Compliance, Greenleaf Health Inc.

Recorded on: Sept. 27, 2019

Description: Data Management expert Israel Heskiel shares best practices for compliance with FDA Data Integrity Title 21 Part 11. He discusses:

  • How to communicate with IT leaders about IT’s role in data integrity compliance;
  • How to establish SOPs and getting IT, QA, the Supply Chain and R&D on the same page;
  • How IT, quality management and regulatory affairs can be scaled for speed and efficiency under the Final Guidance on Data Integrity and Compliance with Drug cGMP; and
  • How to create an “FDA audit IT SWAT team” for continuous improvement.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Israel Heskiel, CEO, CIO, Agrei Consulting

Recorded on: Sept. 25, 2019

Description: Regulatory expert John Smith shares best practices about the approaches the FDA is taking in regard to AI-based image analysis. He discusses:

  • How the FDA views AI within its medical device regulatory paradigm;
  • The different types of computer-assisted image analysis recognized by the FDA;
  • The data that the FDA expects to support AI-based CAD applications; and
  • How the FDA views post-market changes to CAD algorithms.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: John Smith, M.D., J.D., Partner, Hogan Lovells

Recorded on: Sept. 24, 2019

Description: Regulatory expert John Balzano shares best practices for navigating legal and regulatory issues related to healthcare products and services in China. He discusses:

  • Important new regulatory reforms in China related to drug development, including 60-day notification of clinical trial applications, priority review and GCP enforcement;
  • Revisions to Human Genetic Resources (HGR) regulations;
  • How to prepare for overseas inspections and compliance with emerging distribution and manufacturing rules; and
  • How to make sense of the recent guidance documents coming out of China including guidance on foreign data and new application modules.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: John Balzano, Esq., Partner, Covington & Burling LLP

Recorded on: Sept. 19, 2019

Description: Quality systems expert Dan O’Leary shares insights on the EU-MDR’s extensive requirements for documenting, conducting and reporting clinical investigations, including which devices are exempt. He discusses:

  • The role of the clinical investigation in the EU-MDR;
  • Which device types require clinical investigations;
  • How to integrate the EU-MDR and ISO/DIS 14155:2018; and
  • The role of the Notified Body and Competent Authority.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Dan O’Leary, President, Ombu Enterprises, LLC

Recorded on: Sept. 17, 2019

Description: Regulatory expert Barbara Blumenfeld shares information on the FDA’s recently enforced interpretation of its stem cell regulatory framework. She discusses:

  • The FDA regulatory framework in 21 CFR Part 1271 for human cells, tissues and cellular and tissue-based products (HCT/Ps);
  • Enforcement efforts that the FDA has taken since November 2017, including the issuance of warning letters and industry letters and relevant court actions;
  • The FTC’s October 2018 settlement with Regenerative Medical Group and Telehealth Medical Group (California) for false and misleading consumer advertising; and
  • Various opportunities for the legal development and use of stem cells.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Barbara A. Binzak Blumenfeld, Ph.D., Shareholder, Buchanan Ingersoll & Rooney, PC

Recorded on: Aug. 27, 2019

Description: Device expert Connie Hoy shares best practices for implementation of the new Medical Device Single Audit Program (MDSAP) audit protocol. She discusses:

  • The use of the Companion Document to prepare successfully for the MDSAP audit;
  • The use of the quality system to ensure that an organization completely covers specific country requirements;
  • The specifics of the registration review process; and
  • How the MDSAP audit is conducted and how it differs from FDA inspections and ISO audits.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Connie Hoy, Senior Vice President, Regulatory Affairs, Cynosure

Recorded on: Aug. 22, 2019

Description: Industry expert Dan O’Leary shares best practices for preparing for the FDA’s 510(k) design change guidance documents. He discusses:

  • The role of risk management (ISO 14971:2007) in the evaluation process;
  • The decision-making process embodied in the flowcharts;
  • The critera behind the flowchart decision boxes; and
  • How to keep quality records that support your decision.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Dan O’Leary, President, Ombu Enterprises, LLC